Ron Baron Comments on Denali Therapeutics

Guru stock highlight

Author's Avatar
Oct 26, 2021
Summary
  • Shares fell during the quarter.

Denali Therapeutics Inc. (DNLI, Financial) is a biotechnology company developing drugs totreat neurological disorders. Shares fell after an interim update reporting mixed results from its Phase 1/2 study of a program in treating Hunter syndrome. We remain optimistic that Denali will be successful with its suite of approaches targeting the brain.

From Ron Baron (Trades, Portfolio)'s Baron Growth Fund third-quarter 2021 letter.

Disclosures

I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours. Click for the complete disclosure